Journal
PEDIATRIC BLOOD & CANCER
Volume 59, Issue 2, Pages 329-332Publisher
WILEY
DOI: 10.1002/pbc.23319
Keywords
developmental therapeutics; JNJ-26854165; preclinical testing
Categories
Funding
- The National Cancer Institute [NO1-CM-42216, CA21765, CA108786]
Ask authors/readers for more resources
JNJ-26854165 was originally developed as an activator of p53 capable of inducing apoptosis in cancer cell lines. In vitro, JNJ-26854165 demonstrated cytotoxic activity. The ALL cell line panel had a significantly lower median IC50 (0.85?mu M) than the remaining cell lines. In vivo JNJ-26854165 induced significant differences in EFS distribution compared to control in 18 of 37 solid tumors and in 5 of 7 of the evaluable ALL xenografts. Objective responses were observed in 4 of 37 solid tumor xenografts, and 2 of 7 ALL xenografts achieved PR or CR. Responses were noted in xenografts with both mutant and wild-type p53. Pediatr Blood Cancer 2012;59:329332. (c) 2011 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available